Impact on clinical management of a novel blood-derived liquid biopsy (NETest) in patients with neuroendocrine tumors

#3783

Introduction: Despite progresses in NET management, there are persisting challenges regarding initial diagnosis, treatment response assessment and disease follow-up.

Aim(s): To evaluate the clinical utility, and real-world impact of the NETest on NET management.

Materials and methods: Prospective, multicenter, observational study for evaluation of NETest in patients with suspicion (a), newly diagnosed (b), surveillance (c) or progression of NET (d). Primary endpoint: Change in diagnostic/therapeutic decisions based on standard biomarkers, imaging and clinical data versus based on NETest and clinical data only. Blood samples were collected every 3-6 months depending on disease status for 2 years. NETest scores range 0-100 with an upper limit of normal (ULN) of 20. Clinical management will be evaluated by a study-designated MDT, who will perform a case blinded evaluation twice: once, according to ENETS guidelines and second, based on clinical data and NETest scores.

Conference:

Presenting Author: Chirindel A

Authors: Chirindel A, de Dosso S, Wild D, Siebenhüner A, Voegeli M,

Keywords: transcriptomics, biomarker, NETest, clinical management, NET,